Saba Capital Management Discloses New Position in Panacea Acquisition Corp. II
According to a recent Form 13F filing submitted to the SEC, Saba Capital Management disclosed a noteworthy new position in Panacea Acquisition Corp. II (NASDAQ: PANA) stock. Here’s what you need to know about Panacea Acquisition Corp. II, as well as Saba Capital Management’s position in shares of PANA stock:
Saba Capital Management
Founded in 2009, Saba Capital Management L.P. is a registered investment advisor focused on credit and equity relative value strategies. Saba is a spin-out of one of the largest proprietary groups in the industry, ‘Saba Principal Strategies’, founded by Boaz Weinstein at Deutsche Bank in 1998. Saba’s senior investment team began working together at Deutsche Bank in the early 2000s, and is best known for having pioneered credit relative value and capital structure trading strategies. Saba currently manages four core strategies: Credit Relative Value, Tail Hedge, SPACs and Closed-End Funds. Saba’s investors are predominately institutions and include corporate pensions, public pensions, foundations, fund of funds, endowments, and family offices. Saba is 100% self-owned. Saba is headquartered in the historic Chrysler Building in New York and is registered with the SEC and CFTC. You can learn more about Saba Capital Management on their website here.
Saba Capital Management’s New Position in PANA Stock
According to the most recent 13F filing from Saba Capital Management, the institutional investment manager added a meaningful position in Panacea Acquisition Corp. II (NASDAQ: PANA), with 500,000 shares, which represents approximately 2.1236% of the 23,545,001 total PANA shares outstanding. Based on PANA’s last closing price of $9.89 per share, Saba Capital Management’s stake in PANA is worth approximately $4,945,000.00, assuming no change in the position size. If you’re not very familiar with Panacea Acquisition Corp. II, learn more below.
Panacea Acquisition Corp. II (NASDAQ: PANA)
Panacea Acquisition Corp. II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the biotechnology sector. The company was incorporated in 2021 and is based in San Francisco, California.
Be sure to check out more recent 13F filings here to stay up to date on the latest disclosures from institutional investment managers like Saba Capital Management. Also be sure to check out more recent 13F filing analysis news here.